Search

Your search keyword '"Misumi, T."' showing total 341 results

Search Constraints

Start Over You searched for: Author "Misumi, T." Remove constraint Author: "Misumi, T."
341 results on '"Misumi, T."'

Search Results

2. Multidisciplinary Discussion for Fibrotic Hypersensitivity Pneumonitis with a Positive Antigen Avoidance

7. EP08.03-03 S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI

8. EP09.02-03 A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529

9. MA18.08 A Phase 2 Study of Carboplatin, Etoposide and Nintedanib for Unresectable Small-Cell Lung Cancer with Idiopathic Pulmonary Fibrosis

10. Electromagnetic response and pseudo-zero-mode Landau levels of bilayer graphene in a magnetic field

12. 308P Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

13. 1015P Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1 negative or weakly positive advanced non-small cell lung cancer after disease progression on platinum-based therapy: WJOG10317L study (EMERALD)

14. EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL

15. 323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial

16. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study

17. 1263P Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)

19. 554P Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping

21. P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

22. P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study

24. 1285P Final analysis of TORG1936/AMBITIOUS: Phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonia

27. LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)

28. LBA66 Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: A phase III study (ACHILLES/TORG1834)

30. P-149 QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

33. MA13.07 Phase I/II Study of Carboplatin Plus Weekly Nab-Paclitaxel in Aged ≥75 Patients with Squamous-Cell Lung Cancer: TORG1322

38. D abstraction by H at a D-saturated Ru(001) surface

40. MR Measurement of Sub-Micron Scale Relief Structures Fabricated in GMR Materials

Catalog

Books, media, physical & digital resources